In2Bones Announces U.S. Launch of the Avenger Radial Head™ Prosthesis With Sterile, Single-Use Instruments

In2Bones Global, Inc. today announces the U.S. launch of the Avenger Radial Head™ Prosthesis System for primary and revision joint replacement of the radial head. The new prosthesis restores elbow joint function and provides several advantages to surgeons and patients compared with current prosthetic systems.

In2Bones notes this is the first radial head implant to include sterile, single-use instrumentation.

The modularity of the new Avenger Radial Head Prosthesis System — with multiple, highly-polished head and stem sizes — enables surgeons to restore the appropriate height of the radius, which may aid in elbow stability. The new System is also designed with a smooth stem, shown in multiple long-term studies to provide better clinical outcomes than press-fit, ingrowth radial head implant designs.1, 2

The elbow joint is often difficult to access during surgery due to swelling and inflammation caused by trauma. The Avenger System resolves this with tapered and short stem options, allowing for easier insertion and improved implant stability.

“I choose smooth stem radial head implants for my patients because they have shown to have better long-term results,” says Korsh Jafarnia, M.D., orthopedic surgeon and specialist in the hand and upper extremities at Houston Methodist Orthopedics & Sports Medicine. “The In2Bones Avenger Radial Head System is a modern, smooth stem design that is easier to implant due to the tapered and shorter stems.”

Radial head replacements are often performed during trauma surgery with little advanced notice. Thus, there can be tremendous benefits to providers who select implants that include sterile, single-use instruments. Benefits include:

  • Cost savings of as much as $400 per surgery
  • Increased efficiencies because long lead times and delays related to on-site sterilizing processes are bypassed
  • Reduced risks of surgical site infections (SSIs) post-operatively

“Having the instruments and implants sterile and ready to use provides costs savings for my hospital, and assures me that the system will be ready when I’m called in for surgery,” Dr. Jafarnia notes.

“Currently, radial head implant suppliers ship non-sterile instrument sets nationwide for short-notice cases, which can cause potential delays and can increase costs,” explains Jon Simon, Sr. Vice President of Marketing at In2Bones. “The Avenger Radial Head System can be placed on shelves and be ready for immediate use, on-demand. Additionally, surgeons and caregivers can be assured that the sharp, precision instrumentation will only ever contact one patient.”


References

1. T. Flinkkilä, T. Kaisto, K. Sirniö, P. Hyvönen, J. Leppilahti, J. of Bone and Joint Surgery, Short- to mid-term results of metallic press-fit radial head arthroplasty in unstable injuries of the elbow. VOL. 94-B, No. 6, JUNE 2012.

2. Grewal; J. Bone Joint Surg. 2006;88:2192-2200

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”